Form 8-K CONCERT PHARMACEUTICALS, For: Nov 07
- Shares shaky as rate-hike week looms
- Adani responds to Hindenburg report, but stocks continue descent
- Tesla (TSLA) stock earns upgrade to Buy on 'misguided pricing concerns'
- Oil falls as rate hikes loom, Russian flows stay strong
- Dollar seesaws ahead of busy central bank week, euro higher after Spain CPI
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 7, 2022
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction|
|(Address of principal executive offices)||(Zip Code)|
Registrant’s telephone number, including area code: (
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On November 7, 2022, Concert Pharmaceuticals, Inc. announced its financial results for the quarter ended September 30, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
|104||Cover Page Interactive Data File (embedded within the Inline XBRL document)|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|CONCERT PHARMACEUTICALS, INC.|
|Date:||November 7, 2022||By:||/s/ Jeffrey A. Munsie|
|Jeffrey A. Munsie|
|Chief Legal Officer|
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- X METAVERSE PRO explores new easy-to-use features with the support of artificial intelligence and modern technologies in X META Copy Fund
- 111SKIN AND USHOPAL SIGN EXCLUSIVE OMNI-CHANNEL PARTNERSHIP IN CHINA
- Icelandair: Publishing of Q4 and 12M 2022 results
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!